Exosome Sciences (ESI) develops exosome-based solutions to improve identification and monitoring of acute and chronic conditions. Our candidate products are focused toward diagnostic advancements in the fields of oncology, infectious disease and brain injury. Exosomes represent an optimal diagnostic target as diseased or injured cells release these particles into body fluids such as urine, blood, saliva and cerebrospinal fluid where they can be accessed for analysis. Our exosome-based assays unlock the ability to identify proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive “liquid biopsies”. Furthermore, the discovery of disease-specific exosomes will provide disease origin insight necessary to enable personalized clinical management. Our research programs are led by exosome industry pioneers, Dr. Douglas Taylor (Chief Scientific Officer) and Dr. Cicek Gercel-Taylor (Clinical Research Director).
Learn more about the science behind the technology